Zheng Yang1, Xiao-Qing Ye1, Yu-Zhen Zhu2, Zhou Liu3, Ying Zou4, Ying Deng2, Can-Can Guo2, Sushil Kumar Garg5, Jin-Shan Feng6. 1. Department of Psychiatry, Affiliated Hospital of Guangdong Medical College Zhanjiang, China. 2. Department of Pharmacology, Guangdong Medical College Dongguan, China. 3. Department of Neurology, Affiliated Hospital of Guangdong Medical College Zhanjiang, China. 4. Department of Traditional Chinese Medicine, The Second Clinical Medical School, Guangdong Medical College Dongguan, China. 5. Department of Surgery, University of Minnesota Minneapolis, USA. 6. Institute of Traditional Chinese Medicine, Guangdong Medical College Zhanjiang, China.
Abstract
BACKGROUND: Adalimumab is used in an attempt to maintain remission for Ulcerative colitis. This study was to evaluate the efficacy and adverse events of adalimumab compared with placebo in inducing remission of Ulcerative colitis. METHODS: MEDLINE, EMBASE, the Cochrane Controlled Trials Register, OVID, BIOSIS, CNKI, and Google were searched. All randomized trials comparing adalimumab with placebo in inducing remission of moderate-to-severe ulcerative colitis were included. RESULTS: Two randomized controlled trials with a total of 754 participants met the inclusion criteria. The pooled risk ratio (RR) of clinical remission was 1.85 (95% confidence interval (CI) 1.26 to 2.72) following adalimumab treatment. RR of clinical response was 1.40 (95% CI 1.19 to 1.65) while that of mucosal healing was 1.23 (95% CI 1.03 to 1.47). RR of any adverse events was 1.00 (95% CI 0.93 to 1.09). CONCLUSION: Compared with placebo, administration of adalimumab may increase the proportion of patients with moderate-to-severe ulcerative colitis attaining clinical remission, clinical response and mucosal healing. Adalimumab is also tolerated well in these patients.
BACKGROUND:Adalimumab is used in an attempt to maintain remission for Ulcerative colitis. This study was to evaluate the efficacy and adverse events of adalimumab compared with placebo in inducing remission of Ulcerative colitis. METHODS: MEDLINE, EMBASE, the Cochrane Controlled Trials Register, OVID, BIOSIS, CNKI, and Google were searched. All randomized trials comparing adalimumab with placebo in inducing remission of moderate-to-severe ulcerative colitis were included. RESULTS: Two randomized controlled trials with a total of 754 participants met the inclusion criteria. The pooled risk ratio (RR) of clinical remission was 1.85 (95% confidence interval (CI) 1.26 to 2.72) following adalimumab treatment. RR of clinical response was 1.40 (95% CI 1.19 to 1.65) while that of mucosal healing was 1.23 (95% CI 1.03 to 1.47). RR of any adverse events was 1.00 (95% CI 0.93 to 1.09). CONCLUSION: Compared with placebo, administration of adalimumab may increase the proportion of patients with moderate-to-severe ulcerative colitis attaining clinical remission, clinical response and mucosal healing. Adalimumab is also tolerated well in these patients.
Authors: Jean-Baptiste Fraison; Philippe Guilpain; Aurélie Schiffmann; Michel Veyrac; Vincent Le Moing; Philippe Rispail; Alain Le Quellec Journal: J Crohns Colitis Date: 2012-05-29 Impact factor: 9.071
Authors: Walter Reinisch; William J Sandborn; Daniel W Hommes; Geert D'Haens; Stephen Hanauer; Stefan Schreiber; Remo Panaccione; Richard N Fedorak; Mary Beth Tighe; Bidan Huang; Wendy Kampman; Andreas Lazar; Roopal Thakkar Journal: Gut Date: 2011-01-05 Impact factor: 23.059
Authors: C Taxonera; J Estellés; I Fernández-Blanco; O Merino; I Marín-Jiménez; M Barreiro-de Acosta; C Saro; V García-Sánchez; E Gento; G Bastida; J P Gisbert; I Vera; P Martinez-Montiel; S Garcia-Morán; M C Sánchez; J L Mendoza Journal: Aliment Pharmacol Ther Date: 2010-12-07 Impact factor: 8.171
Authors: E J Breese; C A Michie; S W Nicholls; S H Murch; C B Williams; P Domizio; J A Walker-Smith; T T MacDonald Journal: Gastroenterology Date: 1994-06 Impact factor: 22.682
Authors: Waqqas Afif; Jonathan A Leighton; Stephen B Hanauer; Edward V Loftus; William A Faubion; Darrell S Pardi; William J Tremaine; Sunanda V Kane; David H Bruining; Russell D Cohen; David T Rubin; Karen A Hanson; William J Sandborn Journal: Inflamm Bowel Dis Date: 2009-09 Impact factor: 5.325